Acadian Asset Management LLC Has $1.08 Million Stock Position in SCYNEXIS, Inc. (NASDAQ:SCYX)

Acadian Asset Management LLC raised its stake in SCYNEXIS, Inc. (NASDAQ:SCYX) by 28.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 540,683 shares of the company’s stock after buying an additional 119,600 shares during the quarter. Acadian Asset Management LLC owned about 1.43% of SCYNEXIS worth $1,080,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Decheng Capital LLC acquired a new stake in SCYNEXIS in the 4th quarter valued at approximately $1,239,000. Kingdon Capital Management L.L.C. lifted its position in shares of SCYNEXIS by 19.2% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 2,237,048 shares of the company’s stock worth $4,989,000 after purchasing an additional 359,900 shares in the last quarter. Avidity Partners Management LP boosted its holdings in SCYNEXIS by 9.8% during the fourth quarter. Avidity Partners Management LP now owns 1,448,728 shares of the company’s stock worth $3,231,000 after purchasing an additional 129,284 shares during the last quarter. Vanguard Group Inc. grew its position in SCYNEXIS by 8.3% in the first quarter. Vanguard Group Inc. now owns 1,687,670 shares of the company’s stock valued at $2,481,000 after purchasing an additional 129,153 shares in the last quarter. Finally, AMH Equity Ltd increased its stake in SCYNEXIS by 19.9% in the 1st quarter. AMH Equity Ltd now owns 660,000 shares of the company’s stock valued at $970,000 after buying an additional 109,600 shares during the last quarter. Institutional investors and hedge funds own 54.37% of the company’s stock.

SCYNEXIS Stock Up 11.6 %

NASDAQ:SCYX opened at $1.63 on Tuesday. SCYNEXIS, Inc. has a twelve month low of $1.26 and a twelve month high of $3.66. The firm has a market capitalization of $61.58 million, a price-to-earnings ratio of 0.80 and a beta of 1.50. The stock’s 50 day moving average price is $1.79 and its two-hundred day moving average price is $1.82.

SCYNEXIS (NASDAQ:SCYX) last released its earnings results on Thursday, August 8th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.11). SCYNEXIS had a negative net margin of 366.09% and a negative return on equity of 57.41%. The firm had revenue of $0.74 million during the quarter. As a group, analysts anticipate that SCYNEXIS, Inc. will post -0.68 earnings per share for the current year.

Insider Activity at SCYNEXIS

In other SCYNEXIS news, CEO Gonzalez David Angulo purchased 20,000 shares of the stock in a transaction on Thursday, September 12th. The shares were purchased at an average price of $1.37 per share, with a total value of $27,400.00. Following the completion of the transaction, the chief executive officer now directly owns 507,871 shares in the company, valued at $695,783.27. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.85% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Separately, StockNews.com downgraded shares of SCYNEXIS from a “hold” rating to a “sell” rating in a research note on Monday, August 12th.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.